Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Non-current Liabilities
All obligations due after more than one year.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $0, compared with $0 a year earlier.
Context
- Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 214.7M | -0.1% |
| FY2021 | 2021-12-31 | 214.85M | — |
Total Non-current Liabilities vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total non-current liabilities of $0 is the 9th highest of the 11 companies compared; the peer median is $23.94M.
- Total non-current liabilities amounts to 0.0% of total assets for SGMT, versus a peer median of 10.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.32B | +88832.8% | -8.4% | 1.5% | |
| Mar 2026 | $234.17M | -6.0% | -10.9% | 105.4% | |
| Mar 2026 | $82.75M | -22.3% | +11.9% | 74.8% | |
| Mar 2026 | $45.47M | -10.5% | +38.7% | 13.6% | |
| Mar 2026 | $28.2M | -30.1% | +2.2% | 12.9% | |
| Mar 2026 | $19.68M | -59.5% | -26.8% | 8.0% | |
| Mar 2026 | $10.59M | +6.5% | +445.3% | 32.0% | |
| Mar 2026 | $1.9M | -92.5% | -10.1% | 0.8% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding SGMT) | $23.94M | -22.3% | -3.1% | 10.4% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.